At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 39 enrolled
Drug / intervention
Plitidepsin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
In Brief
A Phase 1 clinical trial evaluating Plitidepsin, Bortezomib, and 1 other intervention for Multiple Myeloma. Completed, enrolled 39 participants across 7 sites in 2 countries.
Detailed Summary
Study of Plitidepsin (Aplidin®) to determine the recommended dose (RD) of plitidepsin in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesFrance, Spain
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartJun 2014
Primary CompletionJun 2018
TodayJul 2026
First PostedApr 1, 2014
Enrollment StartJun 1, 2014
Primary CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 12.3 years ago
Interventions
Plitidepsindrug
Bortezomibdrug
Dexamethasonedrug